Search

Displaying results 5481 - 5490 of 6831 in total
  1. Drug

    Nafarelin

    go.drugbank.com/drugs/DB00666
    ApprovedInvestigational

    Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.

  2. Drug

    (S)-Propafenone

    go.drugbank.com/drugs/DB15410
    Investigational

    (S)-Propafenone is under investigation in clinical trial NCT02710669 (New Formulations of Propafenone to Treat Atrial Fibrillation).

  3. Drug

    ETBX-011

    go.drugbank.com/drugs/DB17464
    Investigational

    ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).

  4. Drug

    TUM012

    go.drugbank.com/drugs/DB18652
    Investigational

    TUM012 is a synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine)

  5. Drug

    (R)-Propafenone

    go.drugbank.com/drugs/DB19162
    Investigational

    Propafenone, (r)- is under investigation in clinical trial NCT02710669 (New Formulations of Propafenone to Treat Atrial Fibrillation).

  6. Drug

    Azelastine

    go.drugbank.com/drugs/DB00972
    ApprovedInvestigational

    [L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.

  7. Drug

    Asoprisnil

    go.drugbank.com/drugs/DB06680
    Investigational

    It can be used to treat progesterone sensitive myomata.

  8. Drug

    RAG-17

    go.drugbank.com/drugs/DB18503
    Investigational

    RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).

  9. Drug

    Aminoflavone

    go.drugbank.com/drugs/DB19077
    Investigational

    Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).

  10. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. … To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region.